Newsadmin2019-05-15T18:58:21-04:00

News

Source: NASDAQ

EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU® for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Taiwan
Published on 2020-01-27
EyePoint Pharmaceuticals Announces Preliminary Fourth Quarter and Full-Year 2019 Revenues
Published on 2020-01-23
EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility
Published on 2019-11-19
EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development
Published on 2019-11-14
EyePoint Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Progress
Published on 2019-11-07
EyePoint Pharmaceuticals Announces Addition of DEXYCU® and YUTIQ® to Department of Veteran Affairs Federal Supply Schedule
Published on 2019-11-04
EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU®
Published on 2019-11-01
EyePoint Pharmaceuticals Announces Third Quarter 2019 Financial Results Release Date and Conference Call Information
Published on 2019-10-24
EyePoint Pharmaceuticals Announces Permanent and Specific J-Code for YUTIQ® Now in Effect
Published on 2019-10-02
EyePoint Pharmaceuticals Announces YUTIQ® Presentations at the American Academy of Ophthalmology 2019 Annual Meeting
Published on 2019-09-27
EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
Published on 2019-09-26
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 52nd Annual Retina Society Scientific Meeting
Published on 2019-09-09